I have been talking about the need to increase the funding levels for the Department of Defense (DOD) Peer Review Prostate Cancer Research Program (PCRP) for a long period. This program has proven itself to be the single most valuable government funded prostate cancer research program. The program is designed to fund research projects that [...]
A lot has been written about the need to identify better biomarkers to both assist in the initial diagnosis of prostate cancer and then to help determine which cancers are potentially dangerous from those that are actually indolent. Finding these markers is vital, I too have written about the great need for them. However, in [...]
There is a new web site that will make finding a clinical trial specific for prostate cancer even easier. Not only can you search for trials, but now you can locate the trials by location (distance from your home zip code). Go to: https://web.archive.org/web/20170512051333/http://cancertrials4prostate.org/ or look for the link in the resource section of this [...]
The May 5 issue of the Annals of Internal Medicine carried a report about some recent research looking to identify biomarkers for aggressive prostate cancer. We have been plagued with our inability to differentiate between which prostate cancers are aggressive and will kill and which are actually indolent and will not affect a man’s life. [...]
I have returned from Michigan and again have the computer access and the time to continue sharing items relevant to our struggle. Investigators at the Duke University Prostate Center have indicated that cholesterol-lowering drugs, statins, may reduce inflammation in prostate tumors, which might hinder prostate cancer growth. "Previous studies have shown that men taking statins [...]
The American Association of Cancer Researchers (AACR) is in the midst of its annual scientific research meeting in Denver Colorado. As interesting prostate cancer specific information becomes available I will try and share the news. One of the biggest concerns we face in prostate cancer is in deciding when a cancer needs to be treated. [...]
At the American Association for Cancer Research 100th Annual Meeting 2009 in Denver, National Cancer Institute (NCI) Director John E. Niederhuber, M.D., announced major details, such as funding more grants, development of a platform for personalized cancer care, and an accelerated cancer genetics program, that will move cancer research forward in this new economic environment. [...]
A phase II trial was just completed at the University of Western Australia to investigate changes in bone mineral density (BMD) and osteoporosis in men on intermittent androgen-suppression therapy (IAST) over a period of three years. This trial, conducted at the Faculty of Medicine, University of Western Australia, Crawley, Department of Radiation Oncology, Sir Charles [...]
Senator Barbara Boxer Introduces Cancer-Related Legislation Senator Barbara Boxer (D-CA) has introduced two bills to improve research on prostate cancer and ovarian cancer. S. 756, the "Prostate Research, Imaging, and Men's Education Act (PRIME)" provides for prostate cancer imaging research and education. The reintroduced, S.755 Ovarian Cancer Biomarker Research Act is legislation to develop new [...]
A recent report from England, about the first-generation oral bisphosphonate sodium clodronate, claims to improve overall survival in men with metastatic but not localized prostate cancer, according to long-term data from two randomized controlled trials. Among the sample of 278 men all who had metastatic disease starting and who were responding to long-term hormone therapy, [...]
